Washington Saturday, September 12, 2015, 17:00 Hrs [IST] |
Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company, announced that a favourable Markman ruling has been issued by the United States District Court for the District of Delaware in the patent infringement lawsuit filed by the company against Roxane Laboratories Inc. (Roxane) regarding Roxane’s submission of an Abbreviated New Drug Application to make and sell a generic version of Fanapt, schizophrenia drug.A Markman ruling, also known as a Claim Construction Ruling, is a court ruling in which the judge determines the meaning of key terms from certain disputed patent claims. The Delaware court, which was asked to construe disputed patent claim terms in US patent number 8,586,610 (‘610), rejected Roxane’s proposed construction of all the disputed claim terms. The ‘610 patent is expected to expire in November 2027.Fanapt is an atypical antipsychotic agent indicated for treatment of schizophrenia in adults. In choosing among treatments, prescribers should consider the ability of Fanapt to prolong the QT interval and the use of other drugs first. Prescribers should also consider the need to titrate Fanapt slowly to avoid orthostatic hypotension, which may lead to delayed effectiveness compared to some other drugs that do not require similar titration. |
Vanda gets favorable Markman ruling in Fanapt patent infringement litigation
-
FDA Announces Major Proposed Rule Amending Hatch-Waxman Regulations – Courtesy (Hogan Lovells)
Pharma Live, , Intellectual Property Rights, 0
On February 6, 2015, the Food and Drug Administration (FDA) published in the Federal Register (FR) a comprehensive proposed...
-
Supreme Court Calls For Some Deference In Claim Construction Standard Of Review – Courtesy (Pharma Patents)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 22 JANUARY 2015POSTED IN CLAIM CONSTRUCTION;SUPREME COURT DECISIONSOn January 20, 2015, the Supreme Court issued its...
-
How to apply a patent in European Patent Office (EPO) ?
Pharma Live, , Intellectual Property Rights, 0
How long does a granted patent stay valid? The maximum term of a European patent is 20 years from...
-
Telmisartan: no double-dipping says CJEU, as it avoids answering all the questions – Courtesy (The SPC Blog)
Pharma Live, , Intellectual Property Rights, 0
The Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK...
-
Biogen Inc (BIIB) May Soon Trump Pfizer In Global CNS Drug Sales – Courtesy(bidnessetc.com)
Pharma Live, , Intellectual Property Rights, 0
Pfizer Inc. (NYSE:PFE), presently the world’s largest seller of central nervous system (CNS) drugs, may have its future lead...
-
California Supreme Court Scrutinizes Reverse Payment ANDA Settlements – Courtesy (Pharma Patents)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 12 MAY 2015POSTED IN ANTITRUSTIn In Re Cipro Cases I & II, the California Supreme Court laid...
-
The new drugs war – Courtesy (The Economists)
Pharma Live, , Intellectual Property Rights, 0
OF ALL the goods and services traded in the market economy, pharmaceuticals are perhaps the most contentious. Though produced...
-
Patent office rejects J&J arm’s plea for HIV drug intermediate – Courtesy (Financial Express)
Pharma Live, , Intellectual Property Rights, 0
In a setback to US consumer health behemoth Johnson & Johnson, India’s patent office has rejected an application from...